6 Best Peptides for Osteoarthritis

What to Know Before Choosing a Peptide for Osteoarthritis

Osteoarthritis is one of the more actively researched targets in the peptide space, and the reason is straightforward. The standard treatment options, NSAIDs, corticosteroid injections, and eventually joint replacement, address pain without doing anything to the underlying cartilage damage. That gap is what draws people toward peptides: many of these compounds act on the signaling pathways that govern cartilage repair, synovial inflammation, and tissue remodeling, which is territory conventional medicine has not meaningfully cracked.

A peptide earns a place in this guide if people actually use it for osteoarthritis, or are actively discussing using it. That is the whole test. FDA approval, randomized trial data, and commercial availability are not the filter. A compound prescribed by a telemedicine clinic, a research-only peptide sourced independently, and a Soviet-era bioregulator with a limited English-language literature base are all eligible, as long as real people are reaching for them. Where the evidence is thin, this guide says so plainly.

The six entries below are ordered by how prominently each compound appears in research and documented real-world use for osteoarthritis. That ordering is not a recommendation that one compound is better than another for you. The right compound depends on the specifics of your joints, your history, and what you build alongside a qualified practitioner.

1. BPC-157: For Joint Repair and Connective Tissue Recovery

BPC-157 is a synthetic 15-amino-acid peptide derived from a protein naturally found in human gastric juice. It is arguably the most discussed peptide in the connective tissue and joint repair space, and for osteoarthritis it tends to be the first compound people encounter when they start researching.

The compound works through several overlapping mechanisms. It promotes angiogenesis, the growth of new blood vessels into damaged tissue, which gives repair processes the raw material supply they need to function. It modulates the nitric oxide system to regulate vascular and tissue responses at injury sites. It also appears to upregulate growth hormone receptors in tendon fibroblasts, the cells responsible for maintaining connective tissue structure, which may partly explain why it performs well across both soft tissue and joint contexts.

Most published evidence sits in animal models. Rodent studies on tendon, ligament, and joint healing show consistent effects on tissue repair speed and quality. Human clinical trial data specifically for osteoarthritis has not been published at scale as of 2026. What exists beyond the animal literature is a mix of clinic-reported outcomes from regenerative medicine practices using intra-articular injection and a body of user-reported experience across community protocols. One commercial clinic has cited a high rate of lasting mobility improvements with intra-articular injection, though that figure comes from a practice report rather than a controlled study and should be read accordingly.

Intra-articular injection is the delivery route most often cited for osteoarthritis specifically, because it places the compound directly into the affected joint rather than relying on systemic circulation to reach cartilage tissue. Subcutaneous injection is also widely used, and oral administration appears in some community protocols, though the bioavailability question for oral delivery to deep joint structures remains unresolved.

BPC-157 is not FDA-approved for any indication. It is available as a research chemical. Because it is not produced under regulated pharmaceutical manufacturing standards for consumer use, purity and potency can vary significantly depending on the source. It is commonly combined with TB-500 and GHK-Cu in regenerative medicine contexts, and that trio appears frequently in community protocols for joint recovery.

2. TB-500: For Soft Tissue Repair Surrounding the Joint

TB-500 is a synthetic version of Thymosin Beta-4, a 43-amino-acid protein that occurs naturally in blood platelets and wound fluid. It plays a recognized role in tissue repair at the cellular level, specifically by regulating actin, one of the primary structural proteins cells use to move and respond to injury.

For osteoarthritis, the relevant action is what TB-500 does to the tissue surrounding the joint. Articular cartilage does not exist in isolation. The tendons, ligaments, and soft tissue structures adjacent to a joint contribute to stability and load distribution, and their degradation often runs alongside cartilage loss. TB-500 promotes collagen and elastin proliferation in damaged tissue, reduces local inflammation by upregulating anti-inflammatory cytokines, and facilitates cell migration to injury sites, all of which are relevant to that surrounding soft tissue environment.

The published evidence is primarily preclinical. Animal studies and in vitro work support the repair and anti-inflammatory mechanisms, and TB-500 appears in regenerative medicine literature as a well-regarded peptide for cartilage-adjacent tissue restoration. No large-scale randomized human clinical trial for osteoarthritis has been published as of 2026. Its real-world use is substantial: it appears consistently in community joint-repair protocols and is used at some regenerative medicine clinics off-label, frequently alongside BPC-157.

One note for competitive athletes: Thymosin Beta-4 is listed as a prohibited substance by the World Anti-Doping Agency. That does not affect recreational or medical off-label use, but it is relevant for anyone subject to drug testing.

Like BPC-157, TB-500 is available as a research chemical and is not FDA-approved for any human indication. The general safety profile in available literature is considered reasonable, with injection site reactions and transient fatigue as the most commonly reported effects, though long-term human safety data remains limited.

3. GHK-Cu: For Oxidative Stress and Tissue Remodeling

GHK-Cu is a naturally occurring human plasma peptide, a tripeptide of glycine, histidine, and lysine bound to a copper ion. It is present in relatively high concentrations in young adults and declines significantly with age, which is part of why it has attracted attention in longevity and regenerative medicine research.

Its relevance to osteoarthritis centers on two intersecting processes: oxidative stress and tissue remodeling. Oxidative stress, the accumulation of reactive oxygen molecules that damage cells, is a meaningful driver of chondrocyte death in osteoarthritis. Chondrocytes are the cells responsible for maintaining articular cartilage, and losing them to oxidative damage accelerates joint degeneration. GHK-Cu activates antioxidant pathways that counter this process. Simultaneously, it signals tissue remodeling by activating pathways that clear damaged matrix and stimulate production of new collagen, elastin, and glycosaminoglycans, the structural compounds that give healthy cartilage its load-bearing properties.

GHK-Cu has been extensively studied for wound healing and tissue regeneration, and the wound healing literature is where its strongest evidence sits. Gene expression research suggests it interacts with a large number of genes involved in inflammation, tissue repair, and biological aging. Direct clinical trial data for osteoarthritis is not available as of 2026. The case for its use in joint applications is a scientifically reasonable extrapolation from wound healing and tissue remodeling data, but it should be understood as an extrapolation rather than a direct OA finding.

GHK-Cu is available in topical form widely, primarily as an ingredient in cosmetic serums and creams. The injectable form is available through research chemical channels. For joint applications, injectable is the route used in clinical protocols because topical formulations do not penetrate reliably to deep joint structures. It is not FDA-approved as a drug for any indication. The copper component means long-term or high-dose use warrants monitoring, though copper toxicity at typical peptide protocol levels is rarely reported.

4. Sigumir: For Cartilage and Bone Tissue Regulation

Sigumir is a peptide bioregulator from the Russian scientific tradition of peptide bioregulation, a research program developed primarily at the St. Petersburg Institute of Bioregulation and Gerontology under Professor Vladimir Khavinson. Understanding what a peptide bioregulator is matters here because it represents a genuinely different framework from Western peptide research.

The concept is that short peptides derived from specific tissues, typically from young animals, carry regulatory signals that can be delivered to the corresponding tissue in an aging or damaged recipient. In the case of Sigumir, the target tissue is cartilage and bone. The proposed mechanism is that these short peptides penetrate cell nuclei and normalize gene expression in target tissue cells, restoring metabolic function that has degraded with age or disease. For osteoarthritis, this translates to stimulating chondrocyte activity and extracellular matrix production in articular cartilage.

The evidence base for Sigumir is real but comes almost entirely from Russian and Eastern European scientific literature. English-language peer-reviewed publications are sparse. The studies that exist tend to be small-scale and observational rather than large randomized controlled trials, and independent replication in Western research settings has not occurred at scale. If you are looking for a compound backed by the kind of clinical trial infrastructure familiar in the US or EU, Sigumir is not that compound. What it has is a coherent theoretical framework and a body of work within its own research tradition that carries genuine scientific reasoning, even if it does not translate easily into the Western evidence hierarchy.

Sigumir is typically taken as oral enteric-coated capsules, designed to survive digestion and deliver the peptide for absorption. It is not FDA-approved and is available as a supplement or research product through European and international channels. The oral route and short peptide structure mean the safety profile is generally reported as favorable in the available literature, with no major adverse events appearing in published work.

5. Cartalax: For Cartilage-Specific Cellular Restoration

Cartalax comes from the same Russian peptide bioregulator tradition as Sigumir and was developed by the same research group. Where Sigumir targets both cartilage and bone tissue, Cartalax is designed with a narrower focus on articular cartilage specifically.

Cartalax is a short tripeptide derived from cartilage tissue of young animals. Its proposed mechanism mirrors Sigumir's: delivering regulatory signals to chondrocytes to normalize their gene expression and restore metabolic function. For osteoarthritis, the relevant outcomes would be increased collagen type II synthesis and proteoglycan production, the two components most depleted as OA cartilage degrades. In this framing, Cartalax acts as an epigenetic regulator at the cartilage cell level.

The evidence situation parallels Sigumir's, with the same honest constraints. Research exists within the Russian scientific literature and from the St. Petersburg Institute, covering preclinical work and small observational human studies. English-language peer-reviewed publications are sparse, and independent verification in Western clinical settings is absent. The evidence here is tradition-specific and experiential rather than drawn from a trials infrastructure that would satisfy regulatory agencies in the US or EU. That is not a reason to dismiss it, but it is the accurate description of where it stands.

In community protocols for osteoarthritis, Sigumir and Cartalax are sometimes used together or interchangeably, on the reasoning that their cartilage-targeting mechanisms are complementary, with Sigumir covering the broader joint tissue picture and Cartalax focused more narrowly on the articular surface. Cartalax is available as oral enteric-coated capsules through European and international supplement and research product channels. It is not FDA-approved. No major adverse events appear in the available literature, and the oral route is generally considered low-risk given the short peptide structure.

6. AOD-9604: For Stem Cell-Driven Cartilage Regeneration

AOD-9604 is a modified fragment of human growth hormone, specifically the C-terminal portion of the growth hormone sequence with a small structural modification at one end. It was originally developed as an obesity drug, which is reflected in its name, but its application in regenerative medicine shifted substantially when researchers examined its effects on cartilage biology.

The OA-relevant mechanism is its ability to promote stem cell differentiation into chondrocytes, the cartilage-producing cells. This is a distinct pathway from the anti-inflammatory and tissue-remodeling actions of the other compounds in this guide. Rather than reducing damage or supporting existing tissue, AOD-9604 is aimed at activating the body's capacity to generate new cartilage from precursor cells. Animal studies using intra-articular injection in rabbit models showed improved cartilage morphology, which is the primary published evidence supporting its use in joints. In regenerative medicine clinics, intra-articular injection, often combined with hyaluronic acid as a carrier, is the preferred delivery route for joint applications.

No large-scale human clinical trial for osteoarthritis has been published for AOD-9604 as of 2026. Its use in this context is off-label and largely clinic-driven, with the animal model data and practitioner experience forming the basis. It has been used in regenerative medicine contexts in Australia, where it had a period of therapeutic goods listing before reclassification, and it appears in community protocols for joint repair, though less frequently than BPC-157 or TB-500.

AOD-9604 is not FDA-approved for osteoarthritis or any other indication. It is available as a research chemical. The safety profile in available studies is generally considered favorable, with no serious adverse events widely reported, though long-term human data is limited.

How These Peptides Compare

Frequently Asked Questions

Are Any of These Peptides FDA-Approved for Osteoarthritis?

None of the six peptides in this guide are FDA-approved for osteoarthritis. BPC-157, TB-500, GHK-Cu, and AOD-9604 are classified as research chemicals in the United States. Sigumir and Cartalax are available as supplements or research products through international channels. The only peptide-class compounds with FDA approval relevant to joints are GLP-1 agonists like semaglutide, approved for diabetes and obesity, and teriparatide, approved for osteoporosis, neither of which is approved for osteoarthritis itself.

How Is the Evidence for These Peptides Different from a Standard Drug Trial?

Most of the compounds in this guide have been studied in animal models or in vitro, not in large randomized human clinical trials designed to satisfy drug approval requirements. That does not mean the research is without value; animal model data on tissue repair is meaningful and often predictive. It does mean the evidence is at an earlier stage than what you would expect from a prescription drug, and large-scale human trial data for peptides in osteoarthritis specifically does not yet exist as of 2026.

Do These Peptides Work the Same Way for Everyone?

No, and this matters practically. The compounds here act on biological pathways, including cartilage cell signaling, inflammation, tissue remodeling, and stem cell activity, and those pathways look different depending on the severity of joint damage, overall health, and whether underlying inflammation is being addressed. Individual variability is part of why mapping the field is separate from building a personalized plan, and the latter is what the app handles.

What Is a Peptide Bioregulator, and How Does It Differ from Other Peptides?

A peptide bioregulator is a short peptide derived from a specific tissue type, typically from young animals, intended to deliver regulatory signals to the corresponding tissue in the recipient. The concept was developed in Russian and Eastern European science and centers on the idea that these tissue-specific short peptides normalize gene expression in aging or damaged cells when delivered to the right target. The practical difference from compounds like BPC-157 or GHK-Cu is that bioregulators like Sigumir and Cartalax are taken orally in enteric-coated form rather than injected, and their evidence base comes from a distinct research tradition rather than the Western pharmaceutical trial system.

Is Intra-Articular Injection the Most Effective Route for Joint Peptides?

Intra-articular injection places a compound directly into the joint space, bypassing the need for systemic circulation to carry it to cartilage tissue. For deep joint structures like the knee or hip, this direct delivery is frequently cited as the most effective route for compounds like BPC-157 and AOD-9604. Subcutaneous injection is the more common route in community self-administration protocols and is used for systemic effects. Oral delivery, as used with Sigumir and Cartalax, involves different bioavailability considerations and a different mechanism of action argument altogether. The right delivery choice depends on the compound, the joint, and the clinical context.

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world use of peptides for osteoarthritis in one place.